An Open Label, Phase II Study of Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART

Abbott106 个研究点分布在 10 个国家目标入组 24 人开始时间: 2001年4月最近更新: 2008年4月1日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方: Abbott
入组人数: 24
试验地点: 106
主要终点: Proportion of subjects with plasma HIV RNA levels below the limit of quantification (400 copies/mL) at week 24 and the time until loss of virologic response through week 48

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to study amprenavir/ritonavir, saquinavir/ritonavir or efavirenz in HIV-infected patients following failure with Kaletra (ABT-378/ritonavir) as their first protease inhibitor based HAART.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

结局指标

主要结局

Proportion of subjects with plasma HIV RNA levels below the limit of quantification (400 copies/mL) at week 24 and the time until loss of virologic response through week 48

次要结局

未报告次要终点

研究者

发起方

Abbott

申办方类型

Industry

研究点 (106)

Loading locations...

相似试验

已完成

2 期

Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease InhibitorHIV Infections

NCT00038519Abbott16

已完成

2 期

A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive PatientsHIV Infections

NCT00000912National Institute of Allergy and Infectious Diseases (NIAID)475

已完成

1 期

Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected InfantsHIV Infections

NCT00038480National Institute of Allergy and Infectious Diseases (NIAID)31

已完成

2 期

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and AdolescentsHIV-1

NCT00665847Tibotec Pharmaceuticals, Ireland103

已完成

2 期

A Study to See If Taking One or Two Extra Drugs Can Lower HIV Levels in Patients Who Have Failed Their Anti-HIV Drug TreatmentHIV Infections

NCT00006152National Institute of Allergy and Infectious Diseases (NIAID)42